Lumosa Therapeutics Co., Ltd. (TPEX:6535)
Taiwan
· Delayed Price · Currency is TWD 156.50
-4.50 (-2.80%)
At close: Mar 6, 2026
Lumosa Therapeutics Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Revenue | 35.83 | 39.15 | 56.92 | 26.64 | 17.36 | Upgrade
|
| Revenue Growth (YoY) | -8.49% | -31.21% | 113.63% | 53.45% | -19.81% | Upgrade
|
| Cost of Revenue | 13.96 | 21.44 | 15.44 | 12.08 | 7.47 | Upgrade
|
| Gross Profit | 21.87 | 17.71 | 41.48 | 14.56 | 9.89 | Upgrade
|
| Selling, General & Admin | 51.01 | 51.8 | 47.8 | 40.02 | 34.12 | Upgrade
|
| Research & Development | 304.37 | 322.86 | 369.3 | 280.46 | 406.05 | Upgrade
|
| Operating Expenses | 355.36 | 374.83 | 417.26 | 320.48 | 440.17 | Upgrade
|
| Operating Income | -333.49 | -357.12 | -375.78 | -305.92 | -430.28 | Upgrade
|
| Interest Expense | -0.2 | -0.19 | -0.05 | -0.15 | -0.26 | Upgrade
|
| Interest & Investment Income | 16.07 | 13.43 | 18.49 | 5.84 | 3.46 | Upgrade
|
| Currency Exchange Gain (Loss) | - | 6.87 | -4.21 | 11.02 | -3.73 | Upgrade
|
| Other Non Operating Income (Expenses) | -29 | 2.41 | 2.76 | 2.11 | 1.67 | Upgrade
|
| EBT Excluding Unusual Items | -346.62 | -334.6 | -358.79 | -287.1 | -429.14 | Upgrade
|
| Impairment of Goodwill | - | - | - | - | -78.49 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | -102.24 | 119.08 | -217.4 | 627.61 | Upgrade
|
| Asset Writedown | - | - | -10.37 | - | -24.03 | Upgrade
|
| Other Unusual Items | - | - | - | 0.05 | - | Upgrade
|
| Pretax Income | -346.62 | -436.84 | -250.09 | -504.45 | 95.95 | Upgrade
|
| Income Tax Expense | - | - | 0.25 | 0.04 | - | Upgrade
|
| Earnings From Continuing Operations | -346.62 | -436.84 | -250.33 | -504.48 | 95.95 | Upgrade
|
| Minority Interest in Earnings | 6.08 | 12.05 | 12.29 | 9.82 | - | Upgrade
|
| Net Income | -340.54 | -424.78 | -238.04 | -494.66 | 95.95 | Upgrade
|
| Net Income to Common | -340.54 | -424.78 | -238.04 | -494.66 | 95.95 | Upgrade
|
| Shares Outstanding (Basic) | 166 | 163 | 162 | 162 | 151 | Upgrade
|
| Shares Outstanding (Diluted) | 166 | 163 | 162 | 162 | 151 | Upgrade
|
| Shares Change (YoY) | 1.61% | 0.64% | 0.03% | 7.61% | 24.92% | Upgrade
|
| EPS (Basic) | -2.05 | -2.60 | -1.47 | -3.05 | 0.64 | Upgrade
|
| EPS (Diluted) | -2.05 | -2.60 | -1.47 | -3.05 | 0.64 | Upgrade
|
| Free Cash Flow | -361.16 | -296.78 | -342.53 | -302.74 | -452.69 | Upgrade
|
| Free Cash Flow Per Share | -2.17 | -1.81 | -2.11 | -1.86 | -3.00 | Upgrade
|
| Gross Margin | 61.05% | 45.24% | 72.88% | 54.65% | 56.96% | Upgrade
|
| Operating Margin | -930.73% | -912.09% | -660.23% | -1148.26% | -2478.27% | Upgrade
|
| Profit Margin | -950.41% | -1084.91% | -418.23% | -1856.70% | 552.62% | Upgrade
|
| Free Cash Flow Margin | -1007.96% | -757.97% | -601.82% | -1136.33% | -2607.34% | Upgrade
|
| EBITDA | -322.23 | -353.03 | -356.93 | -288.66 | -403.81 | Upgrade
|
| D&A For EBITDA | 11.26 | 4.09 | 18.85 | 17.26 | 26.47 | Upgrade
|
| EBIT | -333.49 | -357.12 | -375.78 | -305.92 | -430.28 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.